PURPOSEWe aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzuma ...

Patients who achieve pCR after neoadjuvant therapy should continue trastuzumab (with or without pertuzumab) to complete a total of 12 months of anti-HER2 therapy.

The DESTINY-Breast09 trial randomized 1157 patients with locally advanced or metastatic HER2-positive breast cancer to receive either trastuzumab deruxtecan plus pertuzumab (n = 383), trastuzumab ...

Median progression-free survival (PFS) was 40.7 months in the T-DXd-pertuzumab patients and 26.9 months in the taxane plus trastuzumab with pertuzumab patients (P < .00001).

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

After discussion of the case at the national molecular tumor board and a review of literature, the patient was offered first-line treatment with once a week paclitaxel (80 mg/m 2) combined with ...

Swain SM et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

Sixty-three patients were enrolled in the phase 2 IMMUN-HER study (NCT03144947) evaluating SC (n = 32) vs IV (n = 31) trastuzumab administration.In the IV trastuzumab arm, 20 of 31 patients (64.5% ...

"Our findings show that subcutaneous administration was significantly faster than intravenous administration across all measured outcomes, including patient time in the treatment chair (primary ...

WILMINGTON, DE — Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), combined with pertuzumab, delivered a highly ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...